Cortexin
EmergingRussian Rx neurology drug (registered since 1999) — a lyophilized hydrolysate of bovine or porcine cerebral cortex peptides, fractionated… | Peptide · Injectable
Aliases (5)
▸ Reconstitution Lyophilized peptide
Reconstitute lyophilized peptide with bacteriostatic water (BAC) using sterile technique. Calculator below converts vial mg + diluent mL into syringe units.
- 1 Wipe BAC water vial + peptide vial stoppers with isopropyl alcohol.
- 2 Draw the planned diluent volume into a 1 mL syringe.
- 3 Inject diluent slowly down the inside wall of the peptide vial — do NOT spray onto powder.
- 4 Swirl gently (do not shake) until fully dissolved. Solution should be clear.
- 5 Label vial with date reconstituted; refrigerate 2-8 °C.
- 6 Use within 30 days for most peptides (BPC-157 / TB-500 ~ 60 days at 4 °C).
▸ Overview TL;DR
Russian Rx neurology drug (registered since 1999) — a lyophilized hydrolysate of bovine or porcine cerebral cortex peptides, fractionated to the ~1-10 kDa range. Claimed neurotrophic / GABA-modulatory / antioxidant action. Used clinically in Russia for stroke recovery, encephalopathy, post-concussion syndrome, and pediatric ADHD / cognitive disorders. Cerebrolysin is the same concept (porcine-brain peptide hydrolysate, neurotrophic) but with order-of-magnitude better evidence — multi-decade international RCT base, characterized BDNF/GDNF/CNTF-mimetic fractions, 2023 ESO stroke guideline mention. Cortexin's evidence is B-tier Russian-only (stroke, encephalopathy, pediatric ADHD), zero Western replication, zero ClinicalTrials.gov entries, no isolated active peptide. Verdict: SKIP-FOR-NOW. Cerebrolysin already covers the brain-protective animal-cortex-hydrolysate role with better data; Cortexin adds nothing differentiating for Dylan's MMA-subconcussive / cognitive-load thesis. Not a permanent skip — revisit if Western replication appears or if Cerebrolysin produces poor tolerability.
▸ Mechanism of action
Plain English: Cortexin is a powdered extract of cow or pig brain cortex. The manufacturer treats young-animal cerebral cortex tissue with proteolytic enzymes, then filters out everything larger than ~10 kDa, leaving a soup of small peptides and amino acids that gets lyophilized into a vial. You reconstitute the vial with sterile saline or procaine and inject it intramuscularly. The mechanistic claim is that this peptide soup contains "neurotrophic factors" that cross the blood-brain barrier (size-dependent — small peptides can), reach neurons, and provide a generalized survival / plasticity / antioxidant signal. The honest mechanistic state of affairs: no specific peptide within the complex has been isolated and shown to be the active ingredient; no specific receptor has been identified as the binding target; the "neurotrophic cocktail" framing is a category claim, not a mechanism. This is structurally identical to Cerebrolysin's situation — both are animal-cortex peptide hydrolysates with category-level mechanistic claims — but Cerebrolysin has had more characterization work (specific BDNF/GDNF/CNTF-mimetic fractions identified, more peptide-level pharmacology) than Cortexin.
Manufacturer / Khavinson-network claims (not independently verified):
- GABA modulation — Cortexin is reported to enhance GABA-ergic tone, contributing to anxiolytic and anti-epileptic effects observed in Russian clinical practice. No specific GABA-receptor binding data.
- Antioxidant activity — claimed reduction in lipid peroxidation and improvement in superoxide dismutase / catalase activity in animal models.
- Anti-apoptotic — claimed reduction in caspase-3 / pro-apoptotic signaling in stressed neurons (same broad claim made for Pinealon and Cerebrolysin).
- Neurotrophic factor mimicry — claimed to mimic or upregulate BDNF / NGF, supporting neuronal survival and synaptic plasticity. Weakly characterized.
- BBB penetration — claimed for the small-peptide fraction of the complex; not formally PK-characterized.
The Khavinson-network "receptor priming" claim that some external longevity protocols apply to the broader bioregulator family is not specifically established for Cortexin. Cortexin's Russian regulatory and clinical use is as a neurology drug (stroke / encephalopathy / pediatric cognitive disorders), not as a longevity-stack receptor primer. The priming framing is a downstream extrapolation from the Khavinson family-level "short peptides regulate gene expression" hypothesis, and it does not map onto any specific identified mechanism for Cortexin's complex peptide mixture.
Pharmacokinetics:
- Plasma half-life: Not formally characterized. Small peptides typically have minutes-long plasma persistence due to peptidase degradation.
- Bioavailability (IM): Standard IM absorption; specific absorption fraction not published.
- Active metabolite: None established — the active ingredient(s) within the peptide complex have not been isolated.
- Route: IM injection only. Oral form does not exist (the small-peptide complex would be degraded by gut peptidases). This is a meaningful sourcing / friction difference from Pinealon (oral capsule available) but matches Cerebrolysin (IM only).
▸Molecular information Peptide
Glu-Asp-Arg▸ Pharmacokinetics No data
▸Research indications5 use cases
GABA modulation
Most effectiveCortexin is reported to enhance GABA-ergic tone, contributing to anxiolytic and anti-epileptic effects observed in Russian clinical pract…
Antioxidant activity
Effectiveclaimed reduction in lipid peroxidation and improvement in superoxide dismutase / catalase activity in animal models.
Anti-apoptotic
Effectiveclaimed reduction in caspase-3 / pro-apoptotic signaling in stressed neurons (same broad claim made for Pinealon and Cerebrolysin).
Neurotrophic factor mimicry
Moderateclaimed to mimic or upregulate BDNF / NGF, supporting neuronal survival and synaptic plasticity. Weakly characterized.
BBB penetration
Moderateclaimed for the small-peptide fraction of the complex; not formally PK-characterized.
▸Quality indicators6 checks
▸ What to expect Generic
- 1Week 1Injection / administration protocol established. Tolerability check.
- 2Week 2-4Early onset of effect — subtle in most users, noticeable in responders.
- 3Week 4-8Peak benefit window for most peptide cycles.
- 4Week 8+Cycle decision point: continue, taper, or break.
▸ Side effects + safety Tabbed view
Common (>10% users)
None reliably reported above placebo background rate in Russian clinical literature. Cortexin is generally described as well-tolerated.
Less common (1-10%)
- Injection site reaction — local pain, redness, occasional itching. Mild and transient. Most common when reconstituted with saline rather than procaine.
- Mild headache during initial doses. Self-resolves.
- Mild GI discomfort — uncommon.
Rare-serious (<1%)
- Allergic reaction to peptide complex or excipients. Discontinue if hives / swelling / rash develop. Animal-derived peptide hydrolysate carries theoretically higher allergic-reaction risk than synthetic peptides, though clinical reports are rare.
- Theoretical prion / TSE concern (animal-derived): Cortexin is sourced from young calf or pig cerebral cortex. Manufacturers claim sourcing from BSE-free herds and processing methods that inactivate prions. The theoretical risk of bovine spongiform encephalopathy or other transmissible spongiform encephalopathy contamination in animal-CNS-derived products is real but considered low with proper sourcing — the same theoretical concern applies to Cerebrolysin (porcine brain) and is generally regarded as adequately mitigated by manufacturer practices. Not a practical contraindication, but worth flagging for any animal-CNS-derived product.
- No documented organ toxicity in available preclinical literature; no documented dependence; no withdrawal syndrome.
Specific watch periods
- First 1-2 doses: monitor for allergic reaction to animal-derived peptide complex.
- Each course: standard injection-site monitoring.
Theoretical concerns specific to Dylan's profile
- Active malignancy contraindication (theoretical, family-wide): broad pro-survival / anti-apoptotic peptide signaling could theoretically support malignant cell survival. Not personally relevant to Dylan (no oncologic history).
- Stacking with other strongly-pro-survival compounds (BPC-157, TB-500, Cerebrolysin, IGF-1): cumulative pro-survival pressure on cells from stacked anabolic / regenerative peptides is unstudied. Same theoretical concern as for Pinealon.
- No CYP enzyme interactions documented — peptide metabolism via peptidases. Should be drug-interaction-clean.
▸Interactions5 compounds
- cerebrolysinSynergisticMechanistically redundant. Cortexin and Cerebrolysin are both animal-cortex peptide hydrolysates with the same neurotrophic-cocktail claim. Running both is t…
- semax / n-acetyl-semax-amidateSynergisticMechanistically complementary (Semax acts on melanocortin / BDNF / neurotrophic axes; Cortexin's broad peptide-cocktail mechanism is too poorly characterized…
- dylan's V4 antioxidant baseSynergistic(NAC, curcumin, astaxanthin, vitamin C) — likely additive if anything, no interaction concern.
- CerebrolysinAvoidsimultaneously — redundancy without benefit. Run them in separate cycles if running both.
- Other Khavinson-network peptide bioregulators simultaneouslyAvoid(Pinealon, Cerluten, Vesugen) — running multiple Khavinson-network products at once makes attribution impossible and stacks the same single-source-evidence p…
▸References5 sources
Voronina TA, Molodavkin GM, Borlikova GG, Kapitsa IG, Vakhitova YV, Seredenin SB. "Neuroprotective action of Cortexin, Cerebrolysin and Actovegin in acute or chronic brain ischemia in rats." PLoS One 2021;16(7):e0254493. **PMID: 34255796**
2021Head-to-head preclinical comparison: Cortexin (1 or 3 mg/kg) and Cerebrolysin (538 or 1614 mg/kg) showed comparable efficacy in acute and…
Geropharm Cortexin product information
manufacturer's product literature (Russian primary).
CosmicNootropic Cortexin product page
Russian Rx product, IM injectable, 10×10mg vials.
RUPharma Cortexin listing
alternative gray-market vendor.
Cortexin Wikipedia (Russian)
sequence-level mechanism summary, mostly from Russian sources.